Skip to main content
. 2003 Dec;71(12):6899–6905. doi: 10.1128/IAI.71.12.6899-6905.2003

FIG. 2.

FIG. 2.

Prevalence of serum anti-LC3 IgA (A) and IgG antibodies (B) for subjects cured of ALA (light bars) and controls (dark bars). The prevalence of a positive test for each antibody studied was greater in ALA subjects than controls at baseline and during each follow-up period (P < 0.001 for each). The prevalence of serum anti-LC3 IgA antibodies increased in controls only at 9 to 18 months (P < 0.001); in ALA cases there was a decrease in the prevalence of anti-LC3 IgG antibodies during each follow-up period (P < 0.001 compared to the previous period.